blenrep gsk fda - Search News

Order byBest matchMost fresh

News

GSK shares fall

· 8h · on MSN

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

Continue reading

· 13h · on MSN

GSK shares fall after blood cancer drug likely headed for U.S. rejection

GSK blood cancer drug fails to win backing of key US regulatory panel

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results